Evommune (EVMN) Cash & Current Investments (2024 - 2026)
Evommune (EVMN) reported Cash & Current Investments of $211.5 million for Q1 2026, up 3607.29% year-over-year from $5.7 million in Q1 2025, and up 41.73% on a QoQ basis from $149.2 million in Q4 2025.
Evommune (EVMN) has 3 years of Cash & Current Investments data on file, last reported at $211.5 million in Q1 2026.
- Quarterly Cash & Current Investments rose 3607.29% year-over-year to $211.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.5 million (up 3607.29% YoY) and the FY2025 annual result came in at $149.2 million, up 107.11% from the prior year.
- Cash & Current Investments improved to $211.5 million in Q1 2026 per EVMN's latest filing, from $149.2 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $211.5 million in Q1 2026 and bottomed at $5.7 million in Q1 2025.
- The 3-year median for Cash & Current Investments is $74.1 million (2024), against an average of $88.8 million.
- The widest annual swing landed in 2025, when Cash & Current Investments jumped 107.11%; it then soared 3607.29% in 2026.
- Tracing EVMN's Cash & Current Investments over 3 years: stood at $72.0 million in 2024, then jumped by 107.11% to $149.2 million in 2025, then surged by 41.73% to $211.5 million in 2026.
- Per Business Quant, the three latest EVMN Cash & Current Investments figures stand at $211.5 million (Q1 2026), $149.2 million (Q4 2025), and $76.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - | 211.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 211.46 Mn |
| Dec 31, 2025 | 149.20 Mn |
| Sep 30, 2025 | 76.06 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Dec 31, 2024 | 72.04 Mn |
| Sep 30, 2024 | 18.15 Mn |